Regeneron Pharmaceuticals, Inc.
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 2, 2025), Regeneron Pharmaceuticals, Inc. reported 6 stock positions worth $1.2 billion. Its top holding was Alnylam Pharmaceuticals (ALNY) at 97.2% of the portfolio, followed by Intellia Therapeutics (NTLA, 2.1%) and 2SEVENTY Bio (TSVT, 0.5%). Its holdings were unchanged from Q4 2024.
- Most Recent 13F
- Q2 2026
- Location
- TARRYTOWN, NY
- CIK
- 0000872589
- Portfolio Value
- $1.2B (Q1 2025)
- SEC Filing
- 0001104659-25-044118 ↗ filed May 2, 2025
Holdings Value
Holdings 6 stocks · $1.2B
| ALNY Alnylam Pharmaceuticals Inc. | 97.23% | 4,444,445 | $1.2B | No change |
| NTLA Intellia Therapeutics Inc. | 2.13% | 3,702,995 | $26.3M | No change |
| TSVT 2SEVENTY Bio Inc. | 0.50% | 1,254,827 | $6.2M | No change |
| ADVM Adverum Biotechnologies Inc. | 0.06% | 180,909 | $791K | No change |
| ACET Adicet Bio Inc. | 0.06% | 968,183 | $731K | No change |
| BLUEBIRD BIO INC | 0.01% | 21,000 | $102K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| None this quarter. | |||
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||